Lista de obras - Yutaka Fujiwara - Dominio Público Uruguay

A novel serum metabolomics-based diagnostic approach to pancreatic cancer.

artículo científico publicado en 2013

A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors

artículo científico publicado en 2014

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).

artículo científico publicado en 2015

A phase I study of resminostat in Japanese patients with advanced solid tumors

artículo científico publicado en 2015

Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma.

artículo científico publicado en 2017

Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.

artículo científico publicado en 2014

Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.

artículo científico publicado en 2018

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

article

Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.

artículo científico publicado en 2015

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

scientific article published on 13 August 2018

Clinicopathological features in young patients treated for small-cell lung cancer: significance of immunohistological and molecular analyses

artículo científico publicado en 2013

Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.

artículo científico publicado en 2016

Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After Surgery.

artículo científico publicado en 2017

Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.

artículo científico publicado en 2015

Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization.

artículo científico publicado en 2015

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy

artículo científico publicado en 2015

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan

artículo científico publicado en 2017

Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions

artículo científico publicado en 2017

Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients

artículo científico publicado en 2014

Efficacy and safety of osimertinib in a Japanese compassionate use program.

artículo científico publicado en 2017

Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.

artículo científico publicado en 2016

Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.

artículo científico publicado en 2014

Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations

scientific article published on 28 November 2018

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.

artículo científico publicado en 2016

Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study

article

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

artículo científico publicado en 2019

First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors

artículo científico publicado en 2020

Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer

scientific article published on 11 April 2020

Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015

artículo científico publicado en 2018

High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients

artículo científico publicado en 2006

Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines.

artículo científico publicado en 2013

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer

artículo científico publicado en 2015

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer

artículo científico publicado en 2019

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials

artículo científico publicado en 2020

Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification

artículo científico publicado en 2012

Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption

artículo científico publicado en 2018

Left atrial extension of metastatic lung tumor via pulmonary vein: report on the first case of Ewing sarcoma.

artículo científico publicado en 2010

Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study

scientific article published on 20 August 2018

Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited.

artículo científico publicado en 2018

Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer

artículo científico publicado en 2019

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

artículo científico publicado en 2011

Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.

artículo científico publicado en 2012

Medical treatment involving investigational drugs and genetic profile of thymic carcinoma.

artículo científico publicado en 2016

Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer

artículo científico publicado en 2014

Mixed response to osimertinib and the beneficial effects of additional local therapy

artículo científico publicado en 2019

PD-L1 expression in neuroendocrine tumors of the lung.

artículo científico publicado en 2017

Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).

artículo científico publicado en 2015

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism

artículo científico publicado en 2016

Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function.

artículo científico publicado en 2019

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer

scientific article published on 31 December 2018

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

artículo científico publicado en 2016

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.

artículo científico publicado en 2015

Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.

artículo científico publicado en 2010

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.

artículo científico publicado en 2018

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.

artículo científico publicado en 2009

Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.

artículo científico publicado en 2015

Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors

artículo científico publicado en 2007

Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.

artículo científico publicado en 2011

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors

artículo científico publicado en 2016

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.

artículo científico publicado en 2015

Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors

artículo científico publicado en 2015

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

artículo científico publicado en 2009

Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors

artículo científico publicado en 2016

Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.

artículo científico publicado en 2015

Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease

artículo científico publicado en 2019

Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma

artículo científico publicado en 2020

Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.

artículo científico publicado en 2016

Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors

artículo científico publicado en 2016

Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer

artículo científico publicado en 2020

Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer

artículo científico publicado en 2016

Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.

artículo científico publicado en 2014

Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells

artículo científico publicado en 2013

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.

artículo científico publicado en 2015

Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma.

artículo científico publicado en 2015

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.

artículo científico publicado en 2016

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study.

artículo científico publicado en 2018

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF (V600) mutation-positive solid tumors: a phase 1 study.

artículo científico publicado en 2017

Secondary osteosarcoma developing 10 years after chemoradiotherapy for non-small-cell lung cancer

artículo científico publicado en 2013

Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis

artículo científico publicado en 2016

Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan

artículo científico publicado en 2007

Surveillance of protocol deviations in Japanese oncology registration trials: a single institute experience

artículo científico publicado en 2017

The first case of SMARCB1 (INI1) - deficient squamous cell carcinoma of the pleura: a case report.

artículo científico publicado en 2018

The genomic and epigenomic landscape in thymic carcinoma

artículo científico publicado en 2017

Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors

artículo científico publicado en 2019

Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer

scientific article published on 30 October 2020

Tremelimumab-associated tumor regression following after initial progression: two case reports

artículo científico publicado en 2015

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin

artículo científico publicado en 2016

Lista de obras de Yutaka Fujiwara

A novel serum metabolomics-based diagnostic approach to pancreatic cancer.

A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors

A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).

A phase I study of resminostat in Japanese patients with advanced solid tumors

Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma.

Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.

Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.

Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer

Clinicopathological features in young patients treated for small-cell lung cancer: significance of immunohistological and molecular analyses

Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung Cancer.

Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After Surgery.

Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.

Current Status of Single-Agent Phase I Trials in Japan: Toward Globalization.

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan

Effect of sequential chemoradiotherapy in patients with limited-disease small-cell lung cancer who were ineligible for concurrent therapy: a retrospective study at two institutions

Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients

Efficacy and safety of osimertinib in a Japanese compassionate use program.

Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.

Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.

Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.

Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors

Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer

Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015

High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients

Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines.

Impact of KRAS mutation on response and outcome of patients with stage III non-squamous non-small cell lung cancer

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials

Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification

Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption

Left atrial extension of metastatic lung tumor via pulmonary vein: report on the first case of Ewing sarcoma.

Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study

Long-term survival without surgery in NSCLC patients with synchronous brain oligometastasis: systemic chemotherapy revisited.

Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.

Medical treatment involving investigational drugs and genetic profile of thymic carcinoma.

Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer

Mixed response to osimertinib and the beneficial effects of additional local therapy

PD-L1 expression in neuroendocrine tumors of the lung.

Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism

Pharmacokinetic study of the oral fluorouracil antitumor agent S-1 in patients with impaired renal function.

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.

Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.

Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.

Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors

Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.

Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors

Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.

Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease

Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma

Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.

Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors

Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer

Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer

Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide.

Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.

Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma.

Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study.

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF (V600) mutation-positive solid tumors: a phase 1 study.

Secondary osteosarcoma developing 10 years after chemoradiotherapy for non-small-cell lung cancer

Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis